Table 3.
JRQLQ scores at 52‐week treatment (FAS)
| Score | 300 IR (n = 315) | 500 IR (n = 296) | Placebo (n = 316) |
|---|---|---|---|
| Nasal and eye symptoms | 7.17 ± 0.34* | 7.58 ± 0.34 | 8.00 ± 0.33 |
| QOL‐related questionnaires | 9.17 ± 0.89** | 10.45 ± 0.90 | 11.66 ± 0.88 |
| Usual daily activities | 3.37 ± 0.30** | 3.84 ± 0.31 | 4.22 ± 0.30 |
| Outdoor activities | 0.66 ± 0.11** | 0.85 ± 0.11 | 0.98 ± 0.11 |
| Social functioning | 1.16 ± 0.16** | 1.35 ± 0.16 | 1.61 ± 0.16 |
| Impaired sleeping | 0.66 ± 0.07 | 0.68 ± 0.07 | 0.77 ± 0.07 |
| Physical problems | 1.44 ± 0.14* | 1.66 ± 0.15 | 1.76 ± 0.14 |
| Emotional functions | 1.92 ± 0.23 | 2.13 ± 0.23 | 2.32 ± 0.23 |
| General state | 1.54 ± 0.07* | 1.57 ± 0.07 | 1.69 ± 0.07 |
The data are presented as the least squares mean ± standard error.
The mixed‐effects model for repeated measures (MMRM) includes the terms for the treatment group, time, and treatment‐by‐time as fixed effects; and the baseline value, age, gender, sensitization status with autumn allergies, rescue medication use during the pretreatment period, and prior drug for the target disease as covariates.
**P < 0.01, *P < 0.05 compared with placebo.